Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

David S. Siegel, MD PhD, Jonathan L. Kaufman, MD, Noopur S. Raje, MD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Steven P. Treon, MD PhD, Jorge J. Castillo, MD, Linda L. Neuman, MD MBA, Ju RueyJiuan Lee, PhD, Irene Ghobrial, MD

Blood (2014) 124 (21): 1715.

https://doi.org/10.1182/blood.V124.21.1715.1715

Published: 2014

Journal Articles

Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma

Salomon Manier, MD, Antonio Sacco, BS, Patricia Maiso, PhD, Yong Zhang, PhD, Yang Liu, PhD, Yosra Aljawai, BS, Weixin Wang, PhD, Meghan Corrigan-Cummins, Xavier Leleu, MD, PhD, Katherine R. Calvo, MD, PhD, Ola Landgren, M.D., Ph.D., Aldo M. Roccaro, MD, PhD, Irene Ghobrial, MD

Blood (2012) 120 (21): 570.

https://doi.org/10.1182/blood.V120.21.570.570

Published: 2012

Journal Articles

Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia

Yang Liu, PhD, Min Ni, Aldo M. Roccaro, MD, PhD, Xavier Leleu, MD, PhD, Yong Zhang, PhD, Abdel Kareem A. Azab, PhD, BSPharm, Feda Azab, Patricia Maiso, Hai T Ngo, Antonio Sacco, Brittany Morgan, Myles Brown, Irene Ghobrial, MD

Blood (2010) 116 (21): 3620.

https://doi.org/10.1182/blood.V116.21.3620.3620

Published: 2010

Journal Articles

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene Ghobrial, MD, Tiffany Poon, BS, Meghan Rourke, Stacey Chuma, BSN, Janet Kunsman, NP, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul Richardson, M.D., Ph.D., Steven P. Treon, MD, PhD, Jeffrey Matous, MD

Blood (2010) 116 (21): 3952.

https://doi.org/10.1182/blood.V116.21.3952.3952

Published: 2010

Journal Articles

Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma

Rao H Prabhala, PH.D., Mariateresa Fulciniti, PhD, Dheeraj Pelluru, PhD, Puru Nanjappa, MS, Christine Pai, BS, Saem Lee, B.A., Nithya Prabhala, Weihua Song, MD, Constantine S. Mitsiades, MD, PhD, Konstantinos Lefkimmiatis, PhD, Yu-Tzu Tai, PhD, Irene Ghobrial, MD, Paul Richardson, MD, John Daley, Kenneth C. Anderson, MD, Seth Ettenberg, Franco Di Padova, Nikhil C. Munshi, MD

Blood (2010) 116 (21): 456.

https://doi.org/10.1182/blood.V116.21.456.456

Published: 2010

Journal Articles

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Irene Ghobrial, MD, Abdel Kareem A. Azab, PhD, BSPharm, Jacob P. Laubach, MD, MPP, Ranjit Banwait, Meghan Rourke, Phong Quang, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Amy Sam, Eric Still, Brittany Morgan, Kenneth C. Anderson, Paul G Richardson

Blood (2010) 116 (21): 1943.

https://doi.org/10.1182/blood.V116.21.1943.1943

Published: 2010

Journal Articles

The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia

Xavier Leleu, MD, PhD, Wanling Xie, MS, Meghan Rourke, Ranjit Banwait, Renee Leduc, Nitin Roper, Edie Weller, Irene Ghobrial, MD

Blood (2010) 116 (21): 3095.

https://doi.org/10.1182/blood.V116.21.3095.3095

Published: 2010

Journal Articles

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Blood (2010) 116 (21): 3049.

https://doi.org/10.1182/blood.V116.21.3049.3049

Published: 2010

Journal Articles

Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells

Hai T Ngo, Aldo M. Roccaro, MD, PhD, Alexey Leontovich, Yang Liu, PhD, Yong Zhang, PhD, Abdel Kareem A. Azab, PhD, BSPharm, Antonio Sacco, Eric Still, Brittany Morgan, Kenneth C. Anderson, Irene Ghobrial, MD

Blood (2010) 116 (21): 2958.

https://doi.org/10.1182/blood.V116.21.2958.2958

Published: 2010

Journal Articles

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

Blood (2010) 116 (21): 3051.

https://doi.org/10.1182/blood.V116.21.3051.3051

Published: 2010

Journal Articles

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

Blood (2009) 114 (22): 1869.

https://doi.org/10.1182/blood.V114.22.1869.1869

Published: 2009

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Blood (2008) 112 (11): 1742.

https://doi.org/10.1182/blood.V112.11.1742.1742

Published: 2008

Journal Articles

Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling.

Evdoxia Hatjiharissi, MD, Constantine S. Mitsiades, MD,Ph.D, Ciccarelli T. Bryan, Xu Lian, Cao Yang, Sophia Adamia, Ph.D, Xavier Leleu, MD, Aldo Roccaro, MD, Leukothea Ioakimidis, Zachary R. Hunter, Christopher J. Patterson, Irene Ghobrial, MD, Steven P. Treon, MD,Ph.D

Blood (2007) 110 (11): 3174.

https://doi.org/10.1182/blood.V110.11.3174.3174

Published: 2007

Journal Articles

Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom’s Macroglobulinemia.

Aldo Roccaro, MD, Xavier Leleu, MD, Anne-Sophie Moreau, MD, Antonio Sacco, Lian Xu, Evdoxia Hatjiharissi, MD, Bryan Ciccarelli, Christopher Patterson, Sophia Adamia, Domenico Russo, MD, Angelo Vacca, MD, Franco Dammacco, MD, Kenneth Anderson, MD, Irene Ghobrial, MD, Steven Treon, MD

Blood (2007) 110 (11): 1383.

https://doi.org/10.1182/blood.V110.11.1383.1383

Published: 2007

Journal Articles

The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).

Aldo Roccaro, MD, Xavier Leleu, MD, Antonio Sacco, Xiaoying Jia, Anne-Sophie Moreau, MD, Hai Ngo, Abdelkareem Azab, Feda Azab, Evdoxia Hatjiharissi, MD, Steven Treon, MD, Teru Hideshima, MD, Michael Palladino, Kenneth Anderson, MD, Dharminder Chuahan, Irene Ghobrial, MD

Blood (2007) 110 (11): 1516.

https://doi.org/10.1182/blood.V110.11.1516.1516

Published: 2007

Journal Articles

Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom’s Macroglobulinemia.

Xavier Leleu, MD, Garrett O’Sullivan, Xiaoying Jia, Anne-Sophie Moreau, MD, Hai Ngo, Evdoxia Hatjiharisi, MD, Hiroshi Yasui, Zachary Hunter, Yu-Tsu Tai, PhD, Judith Runnels, PhD, Steven Treon, MD, Teru Hideshima, MD, Kenneth Anderson, MD, Irene Ghobrial, MD

Blood (2006) 108 (11): 2517.

https://doi.org/10.1182/blood.V108.11.2517.2517

Published: 2006

Journal Articles

Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).

Marc S. Raab, MD, Klaus Podar, MD, PhD, Jing Zhang, MSc, Douglas McMillin, PhD, Iris Breitkreutz, MD, Yu-Tzu Tai, PhD, Boris Lin, MD, PhD, Irene Ghobrial, MD, Nikhil Munshi, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3466.

https://doi.org/10.1182/blood.V108.11.3466.3466

Published: 2006

Journal Articles

Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia.

Hai T. Ngo, Xavier Leleu, MD, Anne-Sophie Moreau, MD, Evdoxia Hatjiharissi, MD, Xiaoying Jia, Garrett O’Sullivan, Judith Runnels, PhD, Rose Villarreal, Zachary Hunter, Steven Treon, MD,PhD, Teru Hideshima, MD, Kenneth Anderson, MD, Irene Ghobrial, MD

Blood (2006) 108 (11): 4653.

https://doi.org/10.1182/blood.V108.11.4653.4653

Published: 2006

Journal Articles

The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma.

Garrett O’Sullivan, Xavier Leleu, MD, Xiaoying Jia, Evdoxia Hatjiharisi, MD, Hai Ngo, Anne-Sophie Moreau, MD, Yu-Tsu Tai, PhD, Douglas McMillin, Constantine Mitsiades, MD, Noopur Raje, MD, Teru Hideshima, MD, Robert Schlossman, MD, Paul Richardson, MD, Nikhil Munshi, MD, Kenneth Anderson, MD, Irene Ghobrial, MD

Blood (2006) 108 (11): 3495.

https://doi.org/10.1182/blood.V108.11.3495.3495

Published: 2006

Journal Articles

The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.

Xiaoying Jia, Xavier Leleu, MD, Anne-Sophie Moreau, MD, Evdoxia Hatjiharisi, MD, Hai Ngo, Garrett O’Sullivan, Douglas McMillin, PhD, Steven Treon, MD, Constantine Mitsiades, MD, Teru Hideshima, MD, Michael Palladino, Kenneth Anderson, MD, Dharminder Chauhan, PhD, Irene Ghobrial, MD

Blood (2006) 108 (11): 4746.

https://doi.org/10.1182/blood.V108.11.4746.4746

Published: 2006

NARROW

Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM)

Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma

Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling.

Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom’s Macroglobulinemia.

The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).

Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom’s Macroglobulinemia.

Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).

Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia.

The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma.

The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only